Detalhe da pesquisa
1.
Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.
Am J Kidney Dis
; 83(2): 151-161, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726051
2.
Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease.
Am J Kidney Dis
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452919
3.
The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events.
Kidney Int
; 104(6): 1194-1205, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37652206
4.
Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19.
Am J Kidney Dis
; 82(3): 322-332.e1, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263570
5.
Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies.
Am J Kidney Dis
; 81(2): 190-200, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108888
6.
Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
Diabetes Obes Metab
; 25(12): 3779-3787, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722962
7.
Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes.
J Am Soc Nephrol
; 33(9): 1657-1672, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858701
8.
Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D.
J Am Soc Nephrol
; 33(5): 996-1010, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314457
9.
Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury.
J Am Soc Nephrol
; 33(3): 613-627, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017169
10.
Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19.
Am J Kidney Dis
; 79(2): 257-267.e1, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710516
11.
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Cardiovasc Diabetol
; 21(1): 194, 2022 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151557
12.
Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19.
Am J Nephrol
; 53(1): 78-86, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883482
13.
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
Am J Nephrol
; 53(1): 50-58, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034024
14.
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
Am J Nephrol
; 53(1): 21-31, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016188
15.
Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes.
Am J Nephrol
; 53(11-12): 775-785, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630924
16.
High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients.
J Am Soc Nephrol
; 32(9): 2375-2385, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34281958
17.
AKI in Hospitalized Patients with COVID-19.
J Am Soc Nephrol
; 32(1): 151-160, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32883700
18.
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
J Am Soc Nephrol
; 32(1): 161-176, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33067383
19.
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Diabetologia
; 64(10): 2147-2158, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415356
20.
Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.
Diabetologia
; 64(7): 1504-1515, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33797560